Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Cancer Research

• Publication date

  2013-06-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-12-4100PMID 23633484PMCID PMC3686913
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Words of wisdom. Re: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2015cited by this paper
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--response.

  2014cited by this paper
• Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors--letter.

  2014cited by this paper
• Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.

  2013cited by this paper
• Deciphering and reversing tumor immune suppression.

  2013cited by this paper
• Antigen-Specific Bacterial Vaccine Combined with Anti-PD-L1 Rescues Dysfunctional Endogenous T Cells to Reject Long-Established Cancer

  2013cited by this paper
• Therapeutic PD-1 Pathway Blockade Augments with other Modalities of Immunotherapy to Prevent Immune Decline in Ovarian Cancer

  2013cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model

  2012cited by this paper
• Sequential Immunotherapy by Vaccination With GM-CSF–expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors

  2012cited by this paper
• Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.

  2012cited by this paper
• T-regulatory cells: key players in tumor immune escape and angiogenesis.

  2012cited by this paper
• Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody

  2012cited by this paper
• Ligation of Cytotoxic T Lymphocyte Antigen-4 to T Cell Receptor Inhibits T Cell Activation and Directs Differentiation into Foxp3+ Regulatory T Cells*

  2012cited by this paper
• Early T Cell Signalling Is Reversibly Altered in PD-1+ T Lymphocytes Infiltrating Human Tumors

  2011cited by this paper
• T-bet represses expression of PD-1 and sustains virus-specific CD8 T cell responses during chronic infection

  2011cited by this paper
• Tumor immune surveillance and ovarian cancer

  2011cited by this paper
• Tumor-Infiltrating Programmed Death Receptor-1+ Dendritic Cells Mediate Immune Suppression in Ovarian Cancer

  2011cited by this paper
• Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer

  2010cited by this paper
• Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

  2010cited by this paper
• PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

  2010influential reference
• Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates.

  2010cited by this paper
• Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity

  2010cited by this paper
• Integrative genomic analysis of HIV-specific CD8+ T cells reveals that PD-1 inhibits T cell function by upregulating BATF

  2010cited by this paper
• Regulatory T cells in tumor immunity

  2010cited by this paper
• Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals

  2010cited by this paper
• Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

  2010cited by this paper
• Features of responding T cells in cancer and chronic infection.

  2010cited by this paper
• Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Tissue-Specific Differences in PD-1 and PD-L1 Expression during Chronic Viral Infection: Implications for CD8 T-Cell Exhaustion

  2009cited by this paper
• Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

  2009cited by this paper
• PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells.

  2009cited by this paper
• Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired.

  2009cited by this paper
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

  2009cited by this paper
• PD‐1 signaling in primary T cells

  2009cited by this paper
• Control of peripheral T‐cell tolerance and autoimmunity via the CTLA‐4 and PD‐1 pathways

  2008cited by this paper
• PD-1 and its ligands in tolerance and immunity.

  2008cited by this paper
• Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients

  2008cited by this paper
• Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy

  2008cited by this paper
• CTLA-4 Control over Foxp3+ Regulatory T Cell Function

  2008cited by this paper
• Implications of B7-H1 Expression in Clear Cell Carcinoma of the Kidney for Prognostication and Therapy

  2007cited by this paper
• Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

  2007cited by this paper
• Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression.

  2007cited by this paper
• Tregs and rethinking cancer immunotherapy.

  2007cited by this paper
• Molecular signature of CD8+ T cell exhaustion during chronic viral infection.

  2007cited by this paper
• Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer

  2007cited by this paper
• Clinical Significance and Therapeutic Potential of the Programmed Death-1 Ligand/Programmed Death-1 Pathway in Human Pancreatic Cancer

  2007cited by this paper
• Mapping normal and cancer cell signalling networks: towards single-cell proteomics

  2006cited by this paper
• CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells.

  2006cited by this paper
• Cutting Edge: IL-12 Inversely Regulates T-bet and Eomesodermin Expression during Pathogen-Induced CD8+ T Cell Differentiation1

  2006cited by this paper
• Reinvigorating exhausted HIV-specific T cells via PD-1–PD-1 ligand blockade

  2006cited by this paper
• Triggering TLR signaling in vaccination.

  2006cited by this paper
• Restoring function in exhausted CD8 T cells during chronic viral infection

  2006cited by this paper
• Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin

  2005cited by this paper
• Coordinate Analysis of Murine Immune Cell Surface Markers and Intracellular Phosphoproteins by Flow Cytometry1

  2005cited by this paper
• Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A

  2004cited by this paper
• Tumor-infiltrating dendritic cell precursors recruited by a β-defensin contribute to vasculogenesis under the influence of Vegf-A

  2004cited by this paper
• B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression

  2004cited by this paper
• SHP-1 and SHP-2 Associate with Immunoreceptor Tyrosine-Based Switch Motif of Programmed Death 1 upon Primary Human T Cell Stimulation, but Only Receptor Ligation Prevents T Cell Activation1

  2004cited by this paper
• Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

  2004cited by this paper
• CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms

  2004cited by this paper
• B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse.

  2004cited by this paper
• GM-CSF-secreting melanoma vaccines

  2003influential reference
• Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production 1

  2003cited by this paper
• Animal Model Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma

  2002cited by this paper
• CD4+CD25+ suppressor T cells: more questions than answers

  2002cited by this paper
• Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

  2002cited by this paper
• Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

  2002cited by this paper
• Regulation of an Activated S6 Kinase 1 Variant Reveals a Novel Mammalian Target of Rapamycin Phosphorylation Site*

  2002cited by this paper
• Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance

  2001cited by this paper
• Targeting Rare Populations of Murine Antigen-Specific T Lymphocytes by Retroviral Transduction for Potential Application in Gene Therapy for Autoimmune Disease1

  2000cited by this paper
• Development of a syngeneic mouse model for events related to ovarian cancer.

  2000cited by this paper
• T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function.

  1999cited by this paper
• Immune surveillance against a solid tumor fails because of immunological ignorance.

  1999cited by this paper
• Engagement of Cytotoxic T Lymphocyte–associated Antigen 4 (CTLA-4) Induces Transforming Growth Factor β (TGF-β) Production by Murine CD4+ T Cells

  1998cited by this paper
• The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product.

  1996cited by this paper
• Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

  1995cited by this paper
• Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells

  1992cited by this paper
• Microenvironment and Immunology Immune Inhibitory Molecules Lag-3 and Pd-1 Synergistically Regulate T-cell Function to Promote Tumoral Immune Escape

  year unknowncited by this paper

• Disrupting Immune Silence: Non-Coding RNAs Targeting the PD-1/PD-L1 Axis in Tumor Immunity

  2026cites this paper
• A Hybrid PINN-DE Framework for Data-Driven Parameter Estimation of Tumor-Immune Dynamics in Bladder Cancer

  2026cites this paper
• Regulatory T Cells in Ovarian Cancer: Insights into Cancer Immunotherapy.

  2026cites this paper
• Advances in immunotherapy for colorectal cancer: overcoming resistance in mismatch repair-proficient tumors.

  2026cites this paper
• Research Progress on the Formation Mechanism of Immune Suppression Microenvironment in Tumor-Draining Lymph Nodes and Targeted Therapy

  2026cites this paper
• Neoadjuvant immune checkpoint blockade before chemoradiation for cervical squamous carcinoma (GINECO window-of-opportunity COLIBRI study): a phase II trial

  2026cites this paper
• Stoking an anti-liver cancer immune response with cryoablation plus an intratumoral TLR9 agonist and dual checkpoint inhibitors

  2026cites this paper
• Granzyme B‑Targeting Quenched Activity-Based Probes for Assessing Tumor Response to Immunotherapy

  2025cites this paper
• Enhanced potency of immune checkpoint inhibitors against poorly immunological solid tumors by immune stimulatory oncolytic adenoviruses-mediated remodeling of the tumor microenvironment

  2025cites this paper
• Integrated machine learning and single-cell analysis reveal the prognostic and therapeutic potential of SUMOylation-related genes in ovarian cancer

  2025cites this paper
• Promising immunotherapeutic treatments for colon cancer

  2025cites this paper
• Treatment of Ovarian Clear Cell Carcinoma: A Case of Successful Management With Targeted Therapies

  2025cites this paper
• Comprehensive pan-cancer analysis of p62 reveals its contribution to shaping tumor microenvironment and anti-tumor immunity

  2025cites this paper
• Personalized Cancer Vaccines in Combination Therapies: Current Status and Future Prospects

  2025cites this paper
• A novel T-cell proliferation-related model for predicting the prognosis of head and neck squamous cell carcinoma

  2025cites this paper
• Granzyme-targeting quenched activity-based probes for assessing tumor response to immunotherapy

  2025cites this paper
• The characteristics of the tumor immune microenvironment in colorectal cancer with different MSI status and current therapeutic strategies

  2025cites this paper
• Strategies to Overcome PD-1/PD-L1 Blockade Resistance: Focusing on Combination with Immune Checkpoint Blockades

  2025cites this paper
• Inhibiting UPF1 methylation enhances tumor immunotherapy sensitivity by reducing nonsense-mediated mRNA decay.

  2025cites this paper
• Depletion of Effector Regulatory T Cells Associates with Major Response to Induction Dual Immune Checkpoint Blockade

  2025cites this paper
• Co-blocking TIGIT and PVRIG using a novel bispecific antibody enhances anti-tumor immunity.

  2025cites this paper
• Molecular biology of the novel anticancer medications: a focus on kinases inhibitors, biologics and CAR T-cell therapy

  2025cites this paper
• Cationic Peptide Conjugation Enhances Intratumoral Retention and Antitumor Efficacy of Immune Checkpoint Blockade Antibodies.

  2025cites this paper
• Combined cancer immunotherapy with lipid nanoparticle delivery of oligo-based cGAS-agonistic adjuvant and peptide or mRNA vaccines

  2025cites this paper
• Administration of lipid nanoparticle-encapsulated mRNA encoding CCR7, CXCL16 and GITRL effectively mobilizes antitumor T cell immunity.

  2025cites this paper
• Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)

  2025cites this paper
• Bevacizumab, atezolizumab and acetylsalicylic acid in recurrent, platinum-resistant ovarian cancer: the EORTC 1508-GCG phase II study.

  2025cites this paper
• Tumor desialylation surpasses anti‐PD‐L1 checkpoint therapy in restoring anti‐tumor immunity in a murine model for colorectal cancer

  2025cites this paper
• Cancer vaccines as enablers of immunotherapy

  2025cites this paper
• Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases

  2025cites this paper
• Botensilimab (Fc-enhanced anti–CTLA-4 antibody) plus balstilimab (anti–PD-1 antibody) in patients with treatment-refractory ovarian cancer

  2025cites this paper
• Advances in Vaccine-Based Therapies for Pancreatic Cancer

  2025cites this paper
• CCR2 improves tumor directed CAR-T cell trafficking in ovarian cancer

  2025cites this paper
• Potentiation of immune checkpoint blockade with an ITPP radiosensitizer studied with oxygen saturation measurements from photoacoustic imaging

  2025influential citation
• Cancer mRNA vaccines: clinical advances and future opportunities

  2024cites this paper
• One-carbon unit supplementation fuels purine synthesis in tumor-infiltrating T cells and augments checkpoint blockade.

  2024cites this paper
• Single-cell technologies in psoriasis.

  2024cites this paper
• Crosstalk of cell death pathways unveils an autophagy-related gene AOC3 as a critical prognostic marker in colorectal cancer

  2024cites this paper
• Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy

  2024cites this paper
• The senescence journey in cancer immunoediting

  2024cites this paper
• Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis

  2024cites this paper
• Treatment strategies and molecular mechanism of radiotherapy combined with immunotherapy in colorectal cancer.

  2024cites this paper
• Challenges and advances of immune checkpoint therapy

  2024cites this paper
• Combining a WT1 Vaccine (Galinpepimut-S) With Checkpoint Inhibition (Nivolumab) in Patients With WT1–Expressing Diffuse Pleural Mesothelioma: A Phase 1 Study

  2024cites this paper
• Dysfunction and regulatory interplay of T and B cells in chronic hepatitis B: immunotherapy and emerging antiviral strategies

  2024cites this paper
• Tumor-Infiltrating Lymphocytes as Mediators of the Obesity and Papillary Thyroid Carcinoma Lymph Node Metastasis Association: An Observational Retrospective Cohort Study

  2024cites this paper
• Unlocking PD‐1 antibody resistance: The MUC1 DNA vaccine augments CD8+ T cell infiltration and attenuates tumour suppression

  2024cites this paper
• mTOR Deletion Alleviates CD4+ T-Cell Dysfunction in Sepsis through Reducing CTLA4 Accumulation Mediated by Rescuing Autophagy

  2024cites this paper
• Evaluation of regulatory T-cells in cancer immunotherapy: therapeutic relevance of immune checkpoint inhibition

  2024cites this paper
• Association of cuproptosis-related signature with the prognosis of patients with head and neck squamous cell carcinoma

  2024cites this paper
• IGF1R inhibition and PD-1 blockade improve anti-tumor immune response in epithelial ovarian cancer

  2024cites this paper
• The role of programmed death receptor (PD‐)1/PD‐ligand (L)1 in periodontitis and cancer

  2024cites this paper
• Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

  2024cites this paper
• The role of immunotherapy sensitizers and novel immunotherapy modalities in the treatment of cancer

  2024cites this paper
• Evaluating the Impact of Adjunctive Partial Cryoablation on Dual Checkpoint Inhibitor Immunotherapy Response in a Murine Model.

  2024cites this paper
• Examining the evidence for immune checkpoint therapy in high-grade serous ovarian cancer

  2024cites this paper
• Macrophage-derived biomimetic nanoparticles enhanced SDT combined with immunotherapy inhibited tumor growth and metastasis.

  2024cites this paper
• Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy

  2024cites this paper
• Immunotherapy for Ovarian Cancer: Disappointing or Promising?

  2024cites this paper
• Immune checkpoint inhibitors in colorectal cancer: limitation and challenges

  2024cites this paper
• Machine learning-based model for CD4+ conventional T cell genes to predict survival and immune responses in colorectal cancer

  2024influential citation
• Fc–Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies

  2024cites this paper
• Sex hormones and immune regulation in ovarian cancer

  2024cites this paper
• Strategies for overcoming tumour resistance to immunotherapy: harnessing the power of radiation therapy

  2024influential citation
• Dendritic cells as orchestrators of anticancer immunity and immunotherapy

  2024cites this paper
• New hopes and promises in the treatment of ovarian cancer focusing on targeted treatment—a narrative review

  2024cites this paper
• Navigating immunotherapy for ovarian cancer: current landscape and future perspectives

  2024cites this paper
• Detection of Circulating Tumor Cells and Epithelial Progenitor Cells: A Comprehensive Study.

  2023cites this paper
• Global stability and parameter analysis reinforce therapeutic targets of PD-L1-PD-1 and MDSCs for glioblastoma

  2023cites this paper
• One-carbon unit supplementation fuels tumor-infiltrating T cells and augments checkpoint blockade

  2023cites this paper
• Anti-PD1 does not improve pyroptosis induced by γδ T cells but promotes tumor regression in a pleural mesothelioma mouse model

  2023cites this paper
• Albendazole induces an anti-tumor effect and potentiates PD-L1 blockade immunotherapy

  2023cites this paper
• Cancer Vaccine Therapeutics: Limitations and Effectiveness—A Literature Review

  2023cites this paper
• Drug resistance mechanism and reversal strategy in lung cancer immunotherapy

  2023cites this paper
• Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities

  2023cites this paper
• Low molecular weight heparin synergistically enhances the efficacy of adoptive and anti-PD-1-based immunotherapy by increasing lymphocyte infiltration in colorectal cancer

  2023cites this paper
• A phase 1a/1b first-in-human study (COMPASSION-01) evaluating cadonilimab in patients with advanced solid tumors

  2023cites this paper
• Loss of cancer cell‐derived ADAM15 alters the tumor microenvironment in colorectal tumors

  2023cites this paper
• Regulating tumor microenvironments by a lymph node-targeting adjuvant via tumor-specific CTL-derived IFNγ.

  2023cites this paper
• Combining immunotherapy with high-dose radiation therapy (HDRT) significantly inhibits tumor growth in a syngeneic mouse model of high-risk neuroblastoma

  2023cites this paper
• Opportunities and challenges of low-dose radiation to enable immunotherapy efficacy.

  2023cites this paper
• Tumor Microenvironment as a Therapeutic Target in Melanoma Treatment

  2023cites this paper
• Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case Report

  2023cites this paper
• Biodegradable scaffolds for enhancing vaccine delivery

  2023cites this paper
• Overcoming Resistance to Immune Checkpoint Inhibitor Therapy Using Calreticulin-Inducing Nanoparticle

  2023cites this paper
• Engineering a versatile and retrievable cell macroencapsulation device for the delivery of therapeutic proteins

  2023cites this paper
• Obesity-Induced Thymic Involution and Cancer Risk.

  2023cites this paper
• Exosomes-delivered PD-L1 siRNA and CTLA-4 siRNA protect against growth and tumor immune escape in colorectal cancer.

  2023cites this paper
• Cancer Vaccines in the Immunotherapy Era: Promise and Potential

  2023cites this paper
• Immune checkpoint status and exhaustion‐related phenotypes of CD8+ T cells from the tumor‐draining regional lymph nodes in breast cancer

  2023cites this paper
• A Bibliometric Analysis of Melanoma Treated with Vaccinations Research from 2013 to 2023: A Comprehensive Review of the Literature

  2023cites this paper
• Immunotherapy with IL12 and PD1/CTLA4 inhibition is effective in advanced ovarian cancer and associates with reversal of myeloid cell-induced immunosuppression

  2023cites this paper
• Cancer Resistance to Immunotherapy: Comprehensive Insights with Future Perspectives

  2023cites this paper
• Enhancedanti-tumor efficacy through a combination of intramuscularly expressed DNA vaccine and plasmid-encoded PD-1 antibody

  2023cites this paper
• Strategies to Synergize PD-1/PD-L1 Targeted Cancer Immunotherapies to Enhance Antitumor Responses in Ovarian Cancer.

  2023cites this paper
• Role of tumor microenvironment in cancer progression and therapeutic strategy

  2023cites this paper
• The role of macrophages-mediated communications among cell compositions of tumor microenvironment in cancer progression

  2023cites this paper
• Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission

  2023cites this paper
• A Pilot Study to Develop Paraneoplastic Cerebellar Degeneration Mouse Model

  2023cites this paper
• Identification of immunocell infiltrates and effective diagnostic biomarkers in laryngeal carcinoma

  2023cites this paper